Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Spravato antidepressant nasal spray approved in the U.S. for MDD with suicidal ideation

Aug. 4, 2020

FDA approves IND for phase II study of varoglutamstat in Alzheimer's disease

Aug. 4, 2020

Further signs of efficacy seen in trial of AstroRx in amyotrophic lateral sclerosis

Aug. 4, 2020

PDE5 inhibitor AR-1001 affects mechanisms involved in Alzheimer's disease

Aug. 4, 2020

Data presented for OGA inhibitor LY-3372689 in healthy subjects

Aug. 3, 2020

FDA approves Epidiolex for seizures in tuberous sclerosis complex

Aug. 3, 2020

Primary endpoint met with IMU-838 in phase II relapsing-remitting multiple sclerosis trial

Aug. 3, 2020

Recruitment underway for trial of Roche's RO-7248824 in Angelman syndrome

Aug. 3, 2020

Vertex Pharmaceuticals synthesizes new analgesic drugs

Aug. 3, 2020

Clinical evaluation of [18F]EKZ-001 PET radiotracer to quantify HDAC6 brain expression

July 31, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...